PE20110394A1 - Virus sincitial respiratorio vivo atenuado - Google Patents

Virus sincitial respiratorio vivo atenuado

Info

Publication number
PE20110394A1
PE20110394A1 PE2011000971A PE2011000971A PE20110394A1 PE 20110394 A1 PE20110394 A1 PE 20110394A1 PE 2011000971 A PE2011000971 A PE 2011000971A PE 2011000971 A PE2011000971 A PE 2011000971A PE 20110394 A1 PE20110394 A1 PE 20110394A1
Authority
PE
Peru
Prior art keywords
protein coded
gen
gene
protein
glutamic acid
Prior art date
Application number
PE2011000971A
Other languages
English (en)
Spanish (es)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20110394A1 publication Critical patent/PE20110394A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135Respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/544Mucosal route to the airways
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18564Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2011000971A 2008-11-05 2009-11-03 Virus sincitial respiratorio vivo atenuado PE20110394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
PE20110394A1 true PE20110394A1 (es) 2011-06-22

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000971A PE20110394A1 (es) 2008-11-05 2009-11-03 Virus sincitial respiratorio vivo atenuado

Country Status (19)

Country Link
US (1) US9011876B2 (https=)
EP (1) EP2346990B1 (https=)
JP (2) JP5016731B2 (https=)
KR (1) KR20110063863A (https=)
CN (1) CN102272295A (https=)
AU (1) AU2009311287C1 (https=)
BR (1) BRPI0921424A2 (https=)
CA (1) CA2742086A1 (https=)
CL (1) CL2011000999A1 (https=)
CO (1) CO6362047A2 (https=)
EC (1) ECSP11011033A (https=)
IL (1) IL212437A0 (https=)
MA (1) MA32878B1 (https=)
MX (1) MX2011004719A (https=)
PE (1) PE20110394A1 (https=)
RU (1) RU2011122615A (https=)
TN (1) TN2011000182A1 (https=)
WO (1) WO2010053883A1 (https=)
ZA (1) ZA201103259B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2742086A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
EP2744894A4 (en) * 2011-08-18 2015-04-22 Ycine Llc PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
CN113322264B (zh) * 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2019055768A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917592A4 (en) * 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループbの弱毒化の原因である突然変異
CN100354425C (zh) 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
AU2003295339B2 (en) 2002-09-27 2009-03-26 Medimmune, Llc Functional mutations in respiratory syncytial virus
CA2520671C (en) * 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
JPWO2008096811A1 (ja) * 2007-02-07 2010-05-27 ディナベック株式会社 弱毒化マイナス鎖rnaウイルス
CA2742086A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
AU2009311287C1 (en) 2015-02-19
EP2346990A1 (en) 2011-07-27
ZA201103259B (en) 2012-01-25
US9011876B2 (en) 2015-04-21
CA2742086A1 (en) 2010-05-14
CN102272295A (zh) 2011-12-07
EP2346990B1 (en) 2016-01-06
IL212437A0 (en) 2011-06-30
ECSP11011033A (es) 2011-12-30
WO2010053883A1 (en) 2010-05-14
JP2012507302A (ja) 2012-03-29
CL2011000999A1 (es) 2012-07-20
RU2011122615A (ru) 2012-12-20
BRPI0921424A2 (pt) 2016-01-05
JP5743794B2 (ja) 2015-07-01
JP5016731B2 (ja) 2012-09-05
TN2011000182A1 (en) 2012-12-17
AU2009311287B2 (en) 2013-02-07
AU2009311287A1 (en) 2010-05-14
KR20110063863A (ko) 2011-06-14
MX2011004719A (es) 2011-05-31
JP2011250798A (ja) 2011-12-15
CO6362047A2 (es) 2012-01-20
MA32878B1 (fr) 2011-12-01
US20110212130A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
MX2011011960A (es) Peptidos penetradores de celulas.
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
PE20100253A1 (es) Mutantes de fgf21
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
JP2010508030A5 (https=)
PE20090483A1 (es) Vectores para la expresion multiple de genes
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
BRPI0607097A2 (pt) peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada
PE20110106A1 (es) Peptidos mediadores del eflujo del colesterol mejorados
MY167485A (en) Recombinant human interferon-like proteins
DE602007011616D1 (de) Verfahren zur herstellung von oligopeptiden
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2010057242A3 (de) Vakzin
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
RU2013107777A (ru) Поливалентная вакцина против гриппа на основе гибридного белка
EA201290384A1 (ru) Вирусные цитруллинированные пептиды и их применение
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2010039223A3 (en) T-cell immunogens derived from anti-viral proteins and methods of using same

Legal Events

Date Code Title Description
FD Application declared void or lapsed